Anixa Biosciences Announces Treatment Of Second Patient In Its Ovarian Cancer CAR-T Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Anixa Biosciences has announced the treatment of the second patient in its ongoing Phase 1 clinical trial for ovarian cancer CAR-T therapy, in partnership with Moffitt Cancer Center. The trial aims to evaluate safety, determine the maximum tolerated dose, and preliminarily assess clinical activity.
May 22, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anixa Biosciences has treated the second patient in its ongoing Phase 1 clinical trial for ovarian cancer CAR-T therapy, which could potentially impact the company's stock price.
The news of the second patient being treated in Anixa's clinical trial is a positive development for the company, as it shows progress in their research. This could potentially lead to positive results and increased investor interest, which may result in a short-term increase in the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100